Securities Fraud Investigation Into Tandem Diabetes Care, Inc. (TNDM) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

Core Viewpoint - Tandem Diabetes Care, Inc. is under investigation for potential violations of federal securities laws following a malfunction in its insulin pumps that could endanger patients and impact investors [1][2]. Group 1: Company Issues - On August 7, 2025, Tandem disclosed a malfunction in some insulin pumps that could lead to a cessation of insulin delivery, potentially causing hyperglycemia and requiring medical intervention [2]. - The company notified affected customers between July 22 and 24, 2025, regarding the malfunction [2]. Group 2: Market Impact - Following the announcement of the malfunction, Tandem's stock price dropped by $2.87, or 19.9%, closing at $11.52 per share on August 7, 2025, resulting in financial harm to investors [3].